Eli Lilly (LLY)
713.71
-1.49 (-0.21%)
NYSE · Last Trade: May 25th, 3:51 AM EDT
Knowing what Congressional leaders are buying can give investors insight into future legislation that could benefit these companies
Via MarketBeat · May 23, 2025
Via The Motley Fool · May 23, 2025
Growth is oxygen.
But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.
Via StockStory · May 23, 2025
Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide subscription programs.
Via Stocktwits · May 22, 2025
Cigna’s Evernorth has reached agreements with Eli Lilly and Novo Nordisk to reduce prices for GLP-1 weight-loss drugs Wegovy and Zepbound
Via Stocktwits · May 22, 2025
Via Benzinga · May 21, 2025
Despite $6 trillion in promised investments under Trump, Goldman Sachs estimates only $30B–$135B will meaningfully impact U.S. GDP.
Via Benzinga · May 20, 2025
Marjorie Taylor Greene disclosing buying 19 different stocks in a new filing. The buys come less than two weeks after the purchase of 50 different stocks.
Via Benzinga · May 20, 2025
US companies are reshoring manufacturing operations & investing billions in the country, led by Apple & Nvidia for tech, J&J & Eli Lilly for healthcare, Anheuser-Busch for beer, & Cra-Z-Art for toys. Detroit & beyond are benefiting from this trend.
Via Benzinga · May 20, 2025
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants...
Via Benzinga · May 19, 2025
The acquirer says it will continue 23andMe's consumer genome testing services. It acquired a number of programs, including the biobank.
Via Investor's Business Daily · May 19, 2025
Via The Motley Fool · May 18, 2025
Via The Motley Fool · May 18, 2025
Via The Motley Fool · May 17, 2025
Stocks had a strong week on a potential U.S.-China trade deal and cooler inflation data, but volatility may remain as investors shift focus to tax cuts
Via MarketBeat · May 17, 2025
Eli Lilly has steadily gained market share against Novo's Wegovy which finds itself catching up.
Via Talk Markets · May 16, 2025